A global leader in children's vaccines today announced an additional administration route approved by the U.S. Food and Drug Administration (FDA).
Merck confirmed on March 6, 2023, the FDA had approved the addition of the intramuscular (IM) route of administration to the United States Product Insert for Merck's M-M-R®II, VARIVAX®, and ProQuad® vaccines.
Merck says these are the only measles, mumps, rubella, and varicella vaccines that can be administered IM.
These vaccines have already been licensed for IM administration in the European Union.
Read More
